Anti-CTLA4 monoclonal antibody

This page covers all Anti-CTLA4 monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CTLA-4.

Targets

CTLA-4

Phase 3 pipeline (1)

• tremelimumab (anti-CTLA4) · AstraZeneca · Oncology
  Tremelimumab is an anti-CTLA4 monoclonal antibody that blocks the CTLA-4 receptor, enhancing T-cell activation and proliferation.